← Back

Wire · operational-macro

Sanofi gains FDA clearance for Gaucher disease pill

Published

20 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biopharmadive.com →

◆ Verified

Fusion42 · 20 November 2026 · Fusion42 review

Sanofi has received FDA clearance for Infilbray (venglustat), an oral treatment for Gaucher disease, providing the company a new revenue source as Dupixent faces an upcoming patent expiry.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 18 Nov 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

You must adjust your market entry plans as Sanofi's new Gaucher pill clears the FDA, opening treatment opportunities that previously required more invasive therapies. This clearance reshapes competitive dynamics in rare disease drugs, especially as Dupixent revenue declines.

◆ Coverage

6 sources · first reported 18 Nov 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalbiotechrare-diseasepharmadrug-launch